Skip to main content
Premium Trial:

Request an Annual Quote

Exiqon Licenses LNA Technology to Idexx Labs for Veterinary Dx

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Exiqon today announced it has issued a non-exclusive license to Idexx Laboratories for its LNA (locked nucleic acid) technology for veterinary disease diagnostic products.

The deal provides Exiqon with upfront and milestone payments, as well as royalty payments on global sales of products covered by the agreement. Further financial details were not disclosed.

"We are excited that the LNA technology is now being applied in veterinary diagnostic products, which emphasizes the broad applicability of the LNA technology," Lars Kongsbak, president and CEO of Exiqon, said in a statement.

The deal is part of a strategy begun a year ago by the company to license out the technology in markets that Exiqon does not plan to pursue itself.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.